Ec. Johnstone et al., Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients, CANC CHEMOT, 46(6), 2000, pp. 433-441
Purpose: This study was designed to determine individual variation in the m
etabolism of ifosfamide (IF) and any influence this may have on the degree
of DNA damage produced in both peripheral blood lymphocytes (PBL) and in tu
mour tissue. Methods: The pharmacokinetics and metabolism of IF and also of
doxorubicin (DOX) were determined in patients receiving IF/DOX neoadjuvant
chemotherapy for the treatment of advanced breast cancer. The DNA-damaging
effects of this regimen were measured using the comet assay in PBL and in
breast tumour tissue obtained by fine needle aspirate. Parallel in vitro st
udies were carried out in order to establish if DNA damage caused by IF met
abolites or DOX was predictive of cytotoxicity in breast cancer cell lilies
. Results: The median AUG, half-life and clearance of IF were found to be 2
91 muM min, 5.2 h and 66 ml/min per m(2), respectively. A high degree of in
terpatient variability (up to sevenfold) was observed in the metabolism of
both IF and DOX and also in their metabolites. Treatment-related changes in
the amount of DNA damage were observed in both PBL and tumour cells. That
in PBL peaked 48 h after the end of IF infusion (median 17% damaged cells a
t 48 h compared to 4% damaged before treatment). DNA damage in tumour cells
was not elevated above low pretreatment values (median 1.5% damaged cells)
until 3 weeks after IF and DOX treatment (median 30% damaged cells), by wh
ich time damage in PBL showed almost complete resolution to basal levels. T
he DNA damage in PBL determined 24 h after the start of chemotherapy was fo
und to be related to the AUC of 4-hydroxyifosfnmide (40HI; P = 0.05). The a
mount of damage in either tissue did not significantly correlate with clini
cal response or toxicity, but lower amounts of damage were observed in the
tumour cells 3 weeks after treatment in those patients that subsequently re
lapsed, compared to those that remained disease free. DNA damage (more than
20% damaged cells) was observed after exposure to active IF metabolites at
concentrations equal to or greater than the IC50 in MCF-7 and MDA-MB231 ce
ll lines. At concentrations of 4OHI similar to those determined in vivo, an
equivalent level of DNA damage was observed in PBL and in cell lines and w
as associated with significant growth inhibition. DNA damage induced by DOX
was not. predictive of cytotoxicity. Conclusion: Systemic DNA damage appea
red to be related to levels of the active metabolite, consistent with the r
esults of in vitro investigations of DNA damage. Further studies are warran
ted to substantiate this observation and to explore the relationship betwee
n metabolism, DNA damage and antitumour activity.